Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 16, 2021, titled "Glenmark launches SUTIB (Sunitinib) priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%".